PDF factsheet
      Z

Drug eluting stent in coronary artery disease for small vessels, clinical trials results

everolimus eluting stent versus paclitaxel eluting stent
SPIRIT III (small vessel subgroup), 2009
2.5-mm everolimus-eluting stent
versus
2.5-mm paclitaxel-eluting stent
patients included in SPIRIT III that received at least one 2.5-mm stentopen
Follow-up duration: 9 months
paclitaxel eluting stent versus bare-metal stent
TAXUS V small vessels sub groups, 0
paclitaxel-eluting stents
versus
bare metal stents
patients who underwent stent implantation in a single coronary artery stenosis (vessel diameter, 2.25-4.0 mm; lesion length, 10-46 mm), subgroup of small vessel patients
sirolimus eluting stent versus bare-metal stent
SES-SMART, 2004
Cypher
versus
Bx Sonic
Stable AP, ACS, silent myocardial ischaemia as shown by exercise stress testsingle-blind
Follow-up duration: 8 months
Italian
sirolimus eluting stent versus paclitaxel eluting stent
ISAR-SMART 3, 2006
NCT00146575
Taxus
versus
Cypher
Small vessels, de novo lesions in native coronary vessels with a diameter of <2.80 mm nondiabetic patients. AP or positive stress, no AMINA
Germany
SIRTAX (small vessels subgroup), 2005
Cypher
versus
Taxus
Unselected patients. Stable AP, ACS, including AMI. at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation single-blind
Follow-up duration: 9 months
Switzerland

  Options


in first

in second

  Filter